419 related articles for article (PubMed ID: 28327907)
21. The efficacy and safety of everolimus for the treatment of progressive gastroenteropancreatic neuroendocrine tumors: A multi-institution observational study in Taiwan.
Liu CT; Chen MH; Chen JS; Chen LT; Shan YS; Lu CH; Su YL; Ku FC; Chou WC; Chen YY
Asia Pac J Clin Oncol; 2016 Dec; 12(4):396-402. PubMed ID: 27357443
[TBL] [Abstract][Full Text] [Related]
22. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
[TBL] [Abstract][Full Text] [Related]
23. Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.
Fazio N; Buzzoni R; Delle Fave G; Tesselaar ME; Wolin E; Van Cutsem E; Tomassetti P; Strosberg J; Voi M; Bubuteishvili-Pacaud L; Ridolfi A; Herbst F; Tomasek J; Singh S; Pavel M; Kulke MH; Valle JW; Yao JC
Cancer Sci; 2018 Jan; 109(1):174-181. PubMed ID: 29055056
[TBL] [Abstract][Full Text] [Related]
24. Combined Lanreotide Autogel and Temozolomide Treatment of Progressive Pancreatic and Intestinal Neuroendocrine Tumors: The Phase II SONNET Study.
Pavel M; Lahner H; Hörsch D; Rinke A; Denecke T; Koch A; Regnault B; Helbig D; Hoffmanns P; Raderer M
Oncologist; 2024 May; 29(5):e643-e654. PubMed ID: 38206830
[TBL] [Abstract][Full Text] [Related]
25. Everolimus and pasireotide for advanced and metastatic hepatocellular carcinoma.
Sanoff HK; Kim R; Ivanova A; Alistar A; McRee AJ; O'Neil BH
Invest New Drugs; 2015 Apr; 33(2):505-9. PubMed ID: 25613083
[TBL] [Abstract][Full Text] [Related]
26. Target therapies plus somatostatin analogs in NETs: a network meta-analysis.
Pusceddu S; Facciorusso A; Giacomelli L; Prinzi N; Corti F; Niger M; Milione M; Coppa J; Cascella T; Pulice I; Biamonte L; Papa S; Di Bartolomeo M; Shah A; Sacco R; de Braud F
Endocr Relat Cancer; 2021 Jun; 28(7):467-479. PubMed ID: 33979777
[TBL] [Abstract][Full Text] [Related]
27. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
[TBL] [Abstract][Full Text] [Related]
28. Phase I study of the anti-IGF1R antibody cixutumumab with everolimus and octreotide in advanced well-differentiated neuroendocrine tumors.
Dasari A; Phan A; Gupta S; Rashid A; Yeung SC; Hess K; Chen H; Tarco E; Chen H; Wei C; Anh-Do K; Halperin D; Meric-Bernstam F; Yao J
Endocr Relat Cancer; 2015 Jun; 22(3):431-41. PubMed ID: 25900182
[TBL] [Abstract][Full Text] [Related]
29. Everolimus plus octreotide long-acting repeatable in advanced neuroendocrine tumors in the routine tertiary cancer care setting: An Indian experience.
Tippeswamy R; Patil S; Sateesh CT; Shashidhara HP; Prabhudesai S; Prashanth P; Haridas KM
Indian J Cancer; 2015; 52(3):359-62. PubMed ID: 26905137
[TBL] [Abstract][Full Text] [Related]
30. Everolimus for advanced pancreatic neuroendocrine tumors.
Yao JC; Shah MH; Ito T; Bohas CL; Wolin EM; Van Cutsem E; Hobday TJ; Okusaka T; Capdevila J; de Vries EG; Tomassetti P; Pavel ME; Hoosen S; Haas T; Lincy J; Lebwohl D; Öberg K;
N Engl J Med; 2011 Feb; 364(6):514-23. PubMed ID: 21306238
[TBL] [Abstract][Full Text] [Related]
31. Phase I study of combination of pasireotide LAR + gemcitabine in locally advanced or metastatic pancreatic cancer.
Suleiman Y; Mahipal A; Shibata D; Siegel EM; Jump H; Fulp WJ; Springett GM; Kim R
Cancer Chemother Pharmacol; 2015 Sep; 76(3):481-7. PubMed ID: 26126727
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of preclinical efficacy of everolimus and pasireotide in thyroid cancer cell lines and xenograft models.
Owonikoko TK; Zhang G; Lallani SB; Chen Z; Martinson DE; Khuri FR; Lonial S; Marcus A; Sun SY
PLoS One; 2019; 14(2):e0206309. PubMed ID: 30807575
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic sequences in patients with grade 1-2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group.
Faggiano A; Di Maio S; Mocerino C; Ottaviano M; De Divitiis C; Guarnotta V; Dolce P; Modica R; Puliafito I; Tozzi L; Di Sarno A; Leo S; Riccardi F; Palmieri G; Tafuto S; Bianco A; Badalamenti G; Colao A;
Endocrine; 2019 Nov; 66(2):417-424. PubMed ID: 30875056
[TBL] [Abstract][Full Text] [Related]
34. A prospective, phase 1/2 study of everolimus and temozolomide in patients with advanced pancreatic neuroendocrine tumor.
Chan JA; Blaszkowsky L; Stuart K; Zhu AX; Allen J; Wadlow R; Ryan DP; Meyerhardt J; Gonzalez M; Regan E; Zheng H; Kulke MH
Cancer; 2013 Sep; 119(17):3212-8. PubMed ID: 23733618
[TBL] [Abstract][Full Text] [Related]
35. Impact of prior chemotherapy use on the efficacy of everolimus in patients with advanced pancreatic neuroendocrine tumors: a subgroup analysis of the phase III RADIANT-3 trial.
Lombard-Bohas C; Yao JC; Hobday T; Van Cutsem E; Wolin EM; Panneerselvam A; Stergiopoulos S; Shah MH; Capdevila J; Pommier R
Pancreas; 2015 Mar; 44(2):181-9. PubMed ID: 25479584
[TBL] [Abstract][Full Text] [Related]
36. Long-acting somatostatin analogs and well differentiated neuroendocrine tumors: a 20-year-old story.
Faggiano A
J Endocrinol Invest; 2024 Jan; 47(1):35-46. PubMed ID: 37581846
[TBL] [Abstract][Full Text] [Related]
37. A Multicenter Randomized Phase II Study of Single Agent Efficacy and Optimal Combination Sequence of Everolimus and Pasireotide LAR in Advanced Thyroid Cancer.
Bauman JE; Chen Z; Zhang C; Ohr JP; Ferris RL; McGorisk GM; Brandt S; Srivatsa S; Chen AY; Steuer CE; Shin DM; Saba NF; Khuri FR; Owonikoko TK
Cancers (Basel); 2022 May; 14(11):. PubMed ID: 35681620
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.
Yao JC; Phan AT; Chang DZ; Wolff RA; Hess K; Gupta S; Jacobs C; Mares JE; Landgraf AN; Rashid A; Meric-Bernstam F
J Clin Oncol; 2008 Sep; 26(26):4311-8. PubMed ID: 18779618
[TBL] [Abstract][Full Text] [Related]
39. A phase 2 trial of everolimus and pasireotide long-acting release in patients with metastatic uveal melanoma.
Shoushtari AN; Ong LT; Schoder H; Singh-Kandah S; Abbate KT; Postow MA; Callahan MK; Wolchok J; Chapman PB; Panageas KS; Schwartz GK; Carvajal RD
Melanoma Res; 2016 Jun; 26(3):272-7. PubMed ID: 26795274
[TBL] [Abstract][Full Text] [Related]
40. Phase II Study of BEZ235 versus Everolimus in Patients with Mammalian Target of Rapamycin Inhibitor-Naïve Advanced Pancreatic Neuroendocrine Tumors.
Salazar R; Garcia-Carbonero R; Libutti SK; Hendifar AE; Custodio A; Guimbaud R; Lombard-Bohas C; Ricci S; Klümpen HJ; Capdevila J; Reed N; Walenkamp A; Grande E; Safina S; Meyer T; Kong O; Salomon H; Tavorath R; Yao JC
Oncologist; 2018 Jul; 23(7):766-e90. PubMed ID: 29242283
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
